403 related articles for article (PubMed ID: 25728850)
1. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.
Kenmotsu H; Tanigawara Y
Cancer Sci; 2015 May; 106(5):497-504. PubMed ID: 25728850
[TBL] [Abstract][Full Text] [Related]
2. Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.
Syn NL; Wang L; Wong AL; Soe MY; Chuah B; Chan D; Tan SH; Soo RA; Lee SC; Goh BC; Yong WP
Cancer Sci; 2016 Feb; 107(2):173-80. PubMed ID: 26663719
[TBL] [Abstract][Full Text] [Related]
3. Feasibility re-evaluation of 75 mg/m² docetaxel in Japanese patients with previously treated non-small cell lung cancer.
Yamada K; Takeoka H; Mizoguchi Y; Yamashita F; Yoshida T; Zaizen Y; Okayama Y; Naito Y; Azuma K; Hoshino T
Jpn J Clin Oncol; 2014 Apr; 44(4):338-45. PubMed ID: 24482414
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
Minami H; Ohe Y; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y; Nokihara H; Sekine I; Saijo N; Hanada K; Ogata H
J Clin Oncol; 2004 Jul; 22(14):2901-8. PubMed ID: 15254059
[TBL] [Abstract][Full Text] [Related]
5. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.
Fujita K; Yoshino E; Kawara K; Maeda K; Kusuhara H; Sugiyama Y; Yokoyama T; Kaneta T; Ishida H; Sasaki Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):793-801. PubMed ID: 26297058
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors.
Nishio M; Satouchi M; Horiike A; Horio Y; Sunaga Y; Ecstein-Fraisse E; Hida T
Jpn J Clin Oncol; 2018 Apr; 48(4):322-328. PubMed ID: 29514256
[TBL] [Abstract][Full Text] [Related]
7. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
Attard G; Kitzen J; Blagden SP; Fong PC; Pronk LC; Zhi J; Zugmaier G; Verweij J; de Bono JS; de Jonge M
Br J Cancer; 2007 Nov; 97(10):1338-43. PubMed ID: 18000498
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.
Masuda N; Iwata H; Aogi K; Xu Y; Ibrahim A; Gao L; Dalal R; Yoshikawa R; Sasaki Y
Jpn J Clin Oncol; 2016 Dec; 46(12):1088-1094. PubMed ID: 27608646
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia.
Ozawa K; Minami H; Sato H
Yakugaku Zasshi; 2009 Jun; 129(6):749-57. PubMed ID: 19483418
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer.
Mukai H; Takahashi S; Nozawa M; Onozawa Y; Miyazaki J; Ohno K; Suzuki K;
Cancer Chemother Pharmacol; 2014 Apr; 73(4):703-10. PubMed ID: 24488323
[TBL] [Abstract][Full Text] [Related]
11. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours.
Yamamoto N; Boku N; Minami H
Cancer Chemother Pharmacol; 2009 Dec; 65(1):129-36. PubMed ID: 19437020
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
[TBL] [Abstract][Full Text] [Related]
14. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
Cho EK; Park JY; Lee KH; Song HS; Min YJ; Kim YH; Kang JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):9-16. PubMed ID: 24337589
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
Connolly RM; Rudek MA; Garrett-Mayer E; Jeter SC; Donehower MG; Wright LA; Zhao M; Fetting JH; Emens LA; Stearns V; Davidson NE; Baker SD; Wolff AC
Breast Cancer Res Treat; 2011 May; 127(1):153-62. PubMed ID: 21350820
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
[TBL] [Abstract][Full Text] [Related]
17. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
[TBL] [Abstract][Full Text] [Related]
18. The effects of advanced age and serum α
Kenmotsu H; Imamura CK; Ono A; Omori S; Nakashima K; Wakuda K; Taira T; Naito T; Murakami H; Takahashi T; Tanigawara Y
Br J Clin Pharmacol; 2017 Nov; 83(11):2416-2425. PubMed ID: 28640540
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
[TBL] [Abstract][Full Text] [Related]
20. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]